Jennifer Rehm Assistant Professor  - UW Obstetrics and Gynecology, Madison WI

Jennifer Rehm, MD
Assistant Professor

WARF Office Building
610 Walnut Street
Madison, WI 53726

MD - University of Florida, Gainesville, FL
BA - New College of Florida, Sarasota, FL
BS - University of South Florida, Tampa, FL

Research Area/s
My research interests are in clinical research of pediatric obesity and insulin resistance, adipose tissue distribution, polycystic ovary syndrome, and non-alcoholic fatty liver disease (NAFLD). I am utilizing novel MR technology to develop at NAFLD risk assessment model incorporating fasting insulin, total cholesterol, waist circumference, and ethnicity to improve early diagnosis of NAFLD in at risk populations. Future studies will investigate the evolution of adiposity and associated insulin-resistance in middle-school aged girls of different races and ethnicities.

Highlights in your Career
I obtained my medical degree at the University of Florida, where I received both the Leonard Tow Humanism in Medicine Award from the Gold Humanism Honor Society and the Student Hippocratic Award. During my fellowship, I earned the 2011 Pediatric Academic Society Outstanding Fellow Research Award and the Pediatric Endocrine Society Research Fellowship Award.

Personal Passion/s
In addition to clinical research, I coordinate the AFCH Pediatric Adolescent and Transgender Health clinic and have a special interest in working with LBGTQ and gender variant youth.

What I expect to gain by being a scholar for the Center for Women’s Health and Health Disparities.
The BIRCWH program award will provide excellent career and research mentorship, an academic environment designed to nurture critical thinking and professionalism, and access to well-established community and inter-departmental partnerships necessary to develop and conduct clinical investigations. Together, these resources will provide the basis for the development of an independent career in clinical research focusing on the relationship between ectopic adipose tissue and metabolic complications including insulin resistance, PCOS and NAFLD, the development of targeted diagnosis and treatment of fatty liver and associated metabolic disease, and will provide support while I continue to develop the collaborative relationships necessary to conduct a large-scale intervention trial.